Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, et al. A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer. Breast Cancer Res Treat 2022 Dec 23. doi: 10.1007/s10549-022-06844.
PMID: 36562910